Biogen (BIIB) Tops Q2 EPS by $1.12; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $240.98 -0.87%
EPS Growth %: -58.0%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
FNLC, LSBK, OVLY, More
EPS Growth %: -58.0%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.25, $1.12 better than the analyst estimate of $4.13. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.49 billion.
GUIDANCE:
Biogen sees FY2022 EPS of $15.25-$16.75, versus the consensus of $15.54. Biogen sees FY2022 revenue of $9.9-10.1 billion, versus the consensus of $9.84 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- First Bancorp (FNLC) Tops Q3 EPS by 95c
- Graco falls 7% as third quarter results miss estimates
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
